greeksoup/ stock research

Hims & Hers Health, Inc.: Q2 FY2026 earnings call

What management said about Q2 FY2026, from the documents filed with the SEC on 10 August 2026: press release. Guidance figures: 1 raised, 1 lowered, 2 new. The quarter’s numbers.

Key takeaways

  • Revenue rose 38% year-over-year: Second-quarter revenue was $753.2 million, up 38% from $544.8 million. Six-month revenue was $1,361.3 million, up 20% from $1,130.8 million. Source
  • Subscribers reached nearly 2.9 million: Subscribers at June 30 were 2,891 thousand, up 19% from 2,439 thousand. Monthly revenue per average subscriber was $92, up 21% from $76. Source
  • Weight-loss offering moved to GLP-1 access: Management said the US weight-loss offering was evolved to match the global approach to branded GLP-1 access, with compounded GLP-1 offered on a limited scale. Source
  • Gross margin fell to 64%: Gross margin was 64%, against 76% a year earlier. Adjusted gross margin was 64% for the quarter and 67% for six months, against 75%. Source
  • Adjusted EBITDA fell to $60.3 million: Adjusted EBITDA was $60.3 million, an 8% margin, against $82.2 million and 15% a year earlier. Six-month Adjusted EBITDA was $104.6 million, against $173.3 million. Source
  • Free cash flow negative in quarter: Free cash flow was $(68.2) million in the second quarter, against $(69.4) million a year earlier. Net cash used in operating activities was $(35.9) million. Six-month free cash flow was $(15.2) million. Source
  • Eucalyptus closed in June: The company said the June close of the Eucalyptus acquisition strengthened its international business, which grew more than 17-fold in the quarter. Source

“Hims & Hers is delivering a world-class health experience at a global scale and a reasonable price for the nearly 3 million people who rely on us for access to care.”

Andrew Dudum, co-founder and CEO

Guidance

AreaPeriodFigureAgainst last quarter
Revenue Sourcethird quarter 2026$880 million to $900 millionNew
Adjusted EBITDA and margin Sourcethird quarter 2026$75 million to $95 million; margin 9% to 11%New
Revenue Sourcefull year 2026$3.1 billion to $3.3 billionRaised from $2.8 billion to $3.0 billion
Adjusted EBITDA and margin Sourcefull year 2026$275 million to $325 million; margin 9% to 10%Lowered from $275 million to $350 million; margin 10% to 12%

What changed from last quarter

  • Guidance raised: Full-year 2026 revenue guidance was raised. Source
  • Guidance lowered: Full-year Adjusted EBITDA range was updated, with a lower top end and a lower margin range. Source
  • New guidance: Third-quarter 2026 revenue and Adjusted EBITDA guidance was given, after second-quarter guidance in the prior release. Source
  • New: The Eucalyptus acquisition, described as proposed in the prior release, closed in June. Source

Revenue and subscriber growth

  • Revenue rose 38% year-over-year: Second-quarter revenue was $753.2 million, up 38% from $544.8 million. Six-month revenue was $1,361.3 million, up 20% from $1,130.8 million. Source
  • Subscribers reached nearly 2.9 million: Subscribers at June 30 were 2,891 thousand, up 19% from 2,439 thousand. Monthly revenue per average subscriber was $92, up 21% from $76. Source
  • Second-quarter net loss reported: The company reported a second-quarter net loss of $86.3 million. Diluted EPS was $(0.37), against $0.17 a year earlier. Source
  • Six-month results include larger loss: Six-month net loss was $178.4 million, against net income of $92.0 million a year earlier. Six-month diluted EPS was $(0.78). Source

Segments and regions

  • United States revenue up 16%: United States revenue was $621.8 million, up 16% from $537.3 million. Six-month United States revenue was $1,151.7 million, up 3%. Source
  • Rest of the World revenue rose sharply: Rest of the World revenue was $131.4 million, against $7.5 million a year earlier. Six-month figure was $209.6 million, against $14.9 million. Source

“Our second quarter results were defined by a significant re-acceleration in our growth profile and the continued expanding reach of our platform,”

Yemi Okupe, Chief Financial Officer

Products, customers and offerings

  • Most online sales are subscriptions: Management described most online sales as subscription-based, billed on a recurring basis. Customers making one-time purchases are not counted as Subscribers. Source
  • Weight-loss offering moved to GLP-1 access: Management said the US weight-loss offering was evolved to match the global approach to branded GLP-1 access, with compounded GLP-1 offered on a limited scale. Source
  • Branded GLP-1 range expanded in first quarter: In the first quarter, the company said a pivot expanded its branded GLP-1 assortment, with early consumer demand reported as broadening meaningfully.

Margins and costs

  • Gross margin fell to 64%: Gross margin was 64%, against 76% a year earlier. Adjusted gross margin was 64% for the quarter and 67% for six months, against 75%. Source
  • Adjusted EBITDA fell to $60.3 million: Adjusted EBITDA was $60.3 million, an 8% margin, against $82.2 million and 15% a year earlier. Six-month Adjusted EBITDA was $104.6 million, against $173.3 million. Source
  • Marketing and operating costs rose: Marketing expense was $262.2 million, against $217.9 million. Operations and support was $95.5 million, against $66.5 million. Technology and development was $54.9 million, against $37.8 million. Source
  • General and administrative costs rose sharply: General and administrative expense was $165.4 million, against $67.3 million. It included $47.5 million of legal contingencies and $28.8 million of acquisition and transaction-related costs. Source
  • AI and technology efficiencies cited: Management cited meaningful efficiencies from investments in AI and technology, and said they support more affordable high-touch care for customers and wider international reach. Source

“We have never been better positioned to move faster or go further than we are today.”

Andrew Dudum, co-founder and CEO

Legal, restructuring and one-time charges

  • Legal contingencies excluded from Adjusted EBITDA: Legal contingencies were $47.5 million in the second quarter and $62.5 million for six months. The company treats them as non-recurring and excludes them from Adjusted EBITDA. Source
  • Restructuring charges from weight-loss shift: Restructuring and other related charges were $4.6 million in the second quarter and $38.1 million for six months, including $28.5 million recorded within cost of revenue. Source
  • Restructuring charge composition described: Management said the charges consist of inventory write-downs, third-party costs, and non-recurring employee compensation, all incurred from the weight-loss strategic shift. Source

Cash flow and balance sheet

  • Free cash flow negative in quarter: Free cash flow was $(68.2) million in the second quarter, against $(69.4) million a year earlier. Net cash used in operating activities was $(35.9) million. Six-month free cash flow was $(15.2) million. Source
  • Cash balance rose to $609.8 million: Cash and cash equivalents were $609.8 million at June 30, up from $228.6 million at December 31, 2025. Short-term investments were $231.2 million, with no long-term investments. Source
  • Convertible notes balance increased: Convertible senior notes, net, were $1,365.3 million, against $972.6 million at December 31, 2025. Six-month proceeds from issuance were $390.4 million. Source
  • Acquisition-related payables rose: Deferred acquisition payable was $537.4 million current and $165.6 million long-term. Earn-out consideration was $81.4 million current. Accounts payable rose to $501.3 million. Source

Acquisitions and strategy

  • Eucalyptus closed in June: The company said the June close of the Eucalyptus acquisition strengthened its international business, which grew more than 17-fold in the quarter. Source
  • Acquisition cash and deferred consideration: Acquisitions used $318.1 million of cash, net of cash acquired, in the first half. Non-cash contingent and deferred consideration assumed totalled $886.3 million. Source
  • Consumer experience rebuild with AI engine: Management described rebuilding the consumer health experience from the ground up with a doctor-led AI clinical engine, and said customer relationships are deeper and broader. Source

Coming up, as management said on 10 August 2026

  • Domestic growth expected to keep accelerating: Management expects the domestic business to keep accelerating through the second half of 2026. Source

Figures management reported

FigureReported
Subscribers (end of period) Source2,891 thousand, up 19% year-over-year

Risks management discussed

  • Regulatory: Legal contingencies are recorded as non-recurring items and shown separately from Adjusted EBITDA, at $47.5 million in the quarter. Source
  • Operational: Further restructuring and related charges from the weight-loss shift would be presented in the same way as current charges. Source
  • Financial: Changes in fair value of liabilities reduced other results by $4.2 million in the quarter and $21.9 million for six months. Source
  • Financial: Deferred acquisition payables and earn-out consideration are large relative to cash held at June 30, 2026. Source

Earlier plans management reported on

  • Not stated: The first-quarter release said growth would accelerate from that point; the second-quarter release reports re-acceleration in domestic growth.
  • Not stated: Closing was expected in the middle of calendar 2026, subject to conditions; the second-quarter release says the acquisition closed in June.

Other quarters

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.